Wire by Fusion42
Fusion42 Scout Raise
The Debrief & Outliers
Regulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers
Benchmarks
Benchmarks HomeBy News TypeBy RegionBy Sector
AI WeeklyAbout

Switch product

Fusion42RaiseScoutWire

The Debrief & Outliers

All editionsRegulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers

Database & benchmarks

Benchmarks HomeBy News TypeBy RegionBy SectorStories

Account

Sign in
← Back

Wire · opportunities

Amazon Pharmacy Executive: Formularies are Anti-Choice

10 August 2026 · By · Wire by Fusion42

Published

10 August 2026

Topic

opportunities

◆ Sectors

Healthtech Infrastructure

◆ Geography

United States

◆ Source

Read at medcitynews.com →

◆ Verified

Fusion42 · 24 August 2026 · Fusion42 review

Amazon Pharmacy executive and a pharmacy benefits manager CEO criticised formularies as restricting patient choice and driving high drug prices, advocating for transparency and open marketplaces to improve consumer experience in prescription drug pricing.

This Wire brief sits within Fusion42's coverage of Healthtech Infrastructure.

◆ ◆ The Wire takeaway

The grip of formularies on drug pricing is loosening, opening regulatory and market opportunities to build transparent drug marketplaces. You need to start engaging payers and providers now to offer straightforward pricing and alternatives that put the patient first.

◆ Coverage

1 source · 10 Aug 2026

◆ Related on Wire

◆ Topics

Healthtech Infrastructurepharmacy-benefitsdrug-pricingtransparencyformulariesconsumer-choice